Diagnosis of GATA2 defects in the field of autoimmunity and rheumatic immunity is questionable. The clinical performance is complex and often involves multiple systemic burdens. Early identification and standardization of clinical treatment are essential for improving prognosis.
The diagnosis of GATA2 needs to be combined with comprehensive judgments such as clinical performance, imaging inspection, laboratory testing and pathological activation. The platform can assist in matching domestic and foreign experts and teams to provide accurate diagnosis and treatment plans. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune disorders that were previously difficult to treat have been significantly improved.
Therapeutic efficacy and adverse reactions need to be closely monitored throughout the treatment process, and timely adjusted according to the changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of GATA2 deficiencies. Platforms serve China's international medical service system.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.